Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – - Current data package ...
(NASDAQ: AUUD) (“Auddia” or the “Company”) today announced LT350 published its first whitepaper, Distributed, Power-Sovereign AI Infrastructure for the Inference Economy. The whitepaper provides a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results